The aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (PPP) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
200
multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview
CHU de Lille
Lille, France
RECRUITINGCHU de Nimes
Nîmes, France
RECRUITINGCHU de ROUEN
Rouen, France
RECRUITINGtotal duration of treatment in days with strong opioids from day of inclusion
Time frame: 6 months
number of patients exceeding the optimal duration of treatment with strong opioids defined by the SFETD learned society (French Society for the Study and Treatment of Pain) (3 months)
Time frame: 3 months
pain assessment (numerical scale) at first patient call after stopping strong opioids
Time frame: 6 months
number of patients exceeding the optimal duration of treatment with strong opioids defined by the CLUD (Pain Control Committee) of Rouen University Hospital (28 days)
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.